AI주식인사이트AI Stock Insight
B

에이비엘바이오

298380KOSDAQ기초 의약물질 제조업

55.8 / 100

Reference Date: 2026-04-13

Financial Score22.0 / 40
News Sentiment14.8 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 16.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ABL Bio focuses on a growth-oriented business model through technology licensing (License-out) and joint development based on its dual-antibody platform 'Grabody™'. The company addresses unmet medical needs with global technology transfer cases in areas such as ADCs and immuno-oncology therapies. Its U.S. subsidiary, NEOK Bio, manages ADC clinical trials, and cash inflows from milestone achievements in licensing agreements enhance financial stability.

Number of Employees

108people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
—Industry Average 2.033.5Point
ROE
-23.38Industry Average -4.293.5Point

5.4x industry avg (excellent)

Debt Ratio
0.47Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲44.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼1068.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 3Neutral 2Negative 0Average Sentiment Score 68

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 157,700Won52-week high 245,50052-week low 59,700
1-month return0.0Point

1m -16.12% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 1Neutral 6Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-03
  • Neutral주식등의대량보유상황보고서(약식)2026-04-01
  • Positive유상증자결정(종속회사의주요경영사항)2026-03-30
  • Neutral타법인주식및출자증권취득결정2026-03-30
  • Neutral주식매수선택권부여에관한신고2026-03-27